,No. of Mths  Year Ending,variable,value,name
0,Net Sales,12  Jun-15*,62201.0,HCLI
1,Other income,12  Jun-15*,643.0,HCLI
2,Total revenues,12  Jun-15*,62844.0,HCLI
3,Gross profit,12  Jun-15*,-722.0,HCLI
4,Depreciation,12  Jun-15*,519.0,HCLI
5,Interest,12  Jun-15*,1428.0,HCLI
6,Profit before tax,12  Jun-15*,-2025.0,HCLI
7,Minority Interest,12  Jun-15*,0.0,HCLI
8,Prior Period Items,12  Jun-15*,0.0,HCLI
9,Extraordinary Inc (Exp),12  Jun-15*,289.0,HCLI
10,Tax,12  Jun-15*,111.0,HCLI
11,Profit after tax,12  Jun-15*,-1847.0,HCLI
12,Gross profit margin,12  Jun-15*,-1.2,HCLI
13,Effective tax rate,12  Jun-15*,-5.5,HCLI
14,Net profit margin,12  Jun-15*,-3.0,HCLI
15,Current assets,12  Jun-15*,28177.0,HCLI
16,Current liabilities,12  Jun-15*,27219.0,HCLI
17,Net working cap to sales,12  Jun-15*,1.5,HCLI
18,Current ratio,12  Jun-15*,1.0,HCLI
19,Inventory Days,12  Jun-15*,15.0,HCLI
20,Debtors Days,12  Jun-15*,103.0,HCLI
21,Net fixed assets,12  Jun-15*,8114.0,HCLI
22,Share capital,12  Jun-15*,446.0,HCLI
23,"""Free"" reserves",12  Jun-15*,9686.0,HCLI
24,Net worth,12  Jun-15*,10132.0,HCLI
25,Long term debt,12  Jun-15*,2337.0,HCLI
26,Total assets,12  Jun-15*,40042.0,HCLI
27,Interest coverage,12  Jun-15*,-0.4,HCLI
28,Debt to equity ratio,12  Jun-15*,0.2,HCLI
29,Sales to assets ratio,12  Jun-15*,1.6,HCLI
30,Return on assets,12  Jun-15*,-1.0,HCLI
31,Return on equity,12  Jun-15*,-18.2,HCLI
32,Return on capital,12  Jun-15*,-2.5,HCLI
33,Exports to sales,12  Jun-15*,0.0,HCLI
34,Imports to sales,12  Jun-15*,1.4,HCLI
35,Exports (fob),12  Jun-15*,28.0,HCLI
36,Imports (cif),12  Jun-15*,858.0,HCLI
37,Fx inflow,12  Jun-15*,30.0,HCLI
38,Fx outflow,12  Jun-15*,861.0,HCLI
39,Net fx,12  Jun-15*,-831.0,HCLI
40,From Operations,12  Jun-15*,-3692.0,HCLI
41,From Investments,12  Jun-15*,2876.0,HCLI
42,From Financial Activity,12  Jun-15*,-24.0,HCLI
43,Net Cashflow,12  Jun-15*,-840.0,HCLI
44,Net Sales,9  Mar-16*,36562.0,HCLI
45,Other income,9  Mar-16*,1362.0,HCLI
46,Total revenues,9  Mar-16*,37924.0,HCLI
47,Gross profit,9  Mar-16*,-1303.0,HCLI
48,Depreciation,9  Mar-16*,320.0,HCLI
49,Interest,9  Mar-16*,1257.0,HCLI
50,Profit before tax,9  Mar-16*,-1519.0,HCLI
51,Minority Interest,9  Mar-16*,0.0,HCLI
52,Prior Period Items,9  Mar-16*,0.0,HCLI
53,Extraordinary Inc (Exp),9  Mar-16*,-672.0,HCLI
54,Tax,9  Mar-16*,-48.0,HCLI
55,Profit after tax,9  Mar-16*,-2143.0,HCLI
56,Gross profit margin,9  Mar-16*,-3.6,HCLI
57,Effective tax rate,9  Mar-16*,3.1,HCLI
58,Net profit margin,9  Mar-16*,-5.9,HCLI
59,Current assets,9  Mar-16*,23904.0,HCLI
60,Current liabilities,9  Mar-16*,21967.0,HCLI
61,Net working cap to sales,9  Mar-16*,5.3,HCLI
62,Current ratio,9  Mar-16*,1.1,HCLI
63,Inventory Days,9  Mar-16*,21.0,HCLI
64,Debtors Days,9  Mar-16*,155.0,HCLI
65,Net fixed assets,9  Mar-16*,7295.0,HCLI
66,Share capital,9  Mar-16*,446.0,HCLI
67,"""Free"" reserves",9  Mar-16*,7594.0,HCLI
68,Net worth,9  Mar-16*,8039.0,HCLI
69,Long term debt,9  Mar-16*,5282.0,HCLI
70,Total assets,9  Mar-16*,35664.0,HCLI
71,Interest coverage,9  Mar-16*,-0.2,HCLI
72,Debt to equity ratio,9  Mar-16*,0.7,HCLI
73,Sales to assets ratio,9  Mar-16*,1.0,HCLI
74,Return on assets,9  Mar-16*,-2.5,HCLI
75,Return on equity,9  Mar-16*,-26.7,HCLI
76,Return on capital,9  Mar-16*,-7.0,HCLI
77,Exports to sales,9  Mar-16*,0.0,HCLI
78,Imports to sales,9  Mar-16*,0.0,HCLI
79,Exports (fob),9  Mar-16*,0.0,HCLI
80,Imports (cif),9  Mar-16*,0.0,HCLI
81,Fx inflow,9  Mar-16*,9.0,HCLI
82,Fx outflow,9  Mar-16*,20.0,HCLI
83,Net fx,9  Mar-16*,-12.0,HCLI
84,From Operations,9  Mar-16*,-1863.0,HCLI
85,From Investments,9  Mar-16*,3490.0,HCLI
86,From Financial Activity,9  Mar-16*,-880.0,HCLI
87,Net Cashflow,9  Mar-16*,747.0,HCLI
88,Net Sales,12  Mar-17*,32253.0,HCLI
89,Other income,12  Mar-17*,1459.0,HCLI
90,Total revenues,12  Mar-17*,33712.0,HCLI
91,Gross profit,12  Mar-17*,-843.0,HCLI
92,Depreciation,12  Mar-17*,311.0,HCLI
93,Interest,12  Mar-17*,1525.0,HCLI
94,Profit before tax,12  Mar-17*,-1220.0,HCLI
95,Minority Interest,12  Mar-17*,0.0,HCLI
96,Prior Period Items,12  Mar-17*,0.0,HCLI
97,Extraordinary Inc (Exp),12  Mar-17*,-110.0,HCLI
98,Tax,12  Mar-17*,-93.0,HCLI
99,Profit after tax,12  Mar-17*,-1237.0,HCLI
100,Gross profit margin,12  Mar-17*,-2.6,HCLI
101,Effective tax rate,12  Mar-17*,7.6,HCLI
102,Net profit margin,12  Mar-17*,-3.8,HCLI
103,Current assets,12  Mar-17*,20402.0,HCLI
104,Current liabilities,12  Mar-17*,22017.0,HCLI
105,Net working cap to sales,12  Mar-17*,-5.0,HCLI
106,Current ratio,12  Mar-17*,0.9,HCLI
107,Inventory Days,12  Mar-17*,16.0,HCLI
108,Debtors Days,12  Mar-17*,146.0,HCLI
109,Net fixed assets,12  Mar-17*,6397.0,HCLI
110,Share capital,12  Mar-17*,446.0,HCLI
111,"""Free"" reserves",12  Mar-17*,5048.0,HCLI
112,Net worth,12  Mar-17*,5494.0,HCLI
113,Long term debt,12  Mar-17*,4132.0,HCLI
114,Total assets,12  Mar-17*,31840.0,HCLI
115,Interest coverage,12  Mar-17*,0.2,HCLI
116,Debt to equity ratio,12  Mar-17*,0.8,HCLI
117,Sales to assets ratio,12  Mar-17*,1.0,HCLI
118,Return on assets,12  Mar-17*,0.9,HCLI
119,Return on equity,12  Mar-17*,-22.5,HCLI
120,Return on capital,12  Mar-17*,2.0,HCLI
121,Exports to sales,12  Mar-17*,0.0,HCLI
122,Imports to sales,12  Mar-17*,0.0,HCLI
123,Exports (fob),12  Mar-17*,0.0,HCLI
124,Imports (cif),12  Mar-17*,0.0,HCLI
125,Fx inflow,12  Mar-17*,69.0,HCLI
126,Fx outflow,12  Mar-17*,1262.0,HCLI
127,Net fx,12  Mar-17*,-1193.0,HCLI
128,From Operations,12  Mar-17*,773.0,HCLI
129,From Investments,12  Mar-17*,-27.0,HCLI
130,From Financial Activity,12  Mar-17*,-1354.0,HCLI
131,Net Cashflow,12  Mar-17*,-608.0,HCLI
132,Net Sales,12  Mar-18*,35646.0,HCLI
133,Other income,12  Mar-18*,1307.0,HCLI
134,Total revenues,12  Mar-18*,36954.0,HCLI
135,Gross profit,12  Mar-18*,-1342.0,HCLI
136,Depreciation,12  Mar-18*,275.0,HCLI
137,Interest,12  Mar-18*,1411.0,HCLI
138,Profit before tax,12  Mar-18*,-1721.0,HCLI
139,Minority Interest,12  Mar-18*,0.0,HCLI
140,Prior Period Items,12  Mar-18*,0.0,HCLI
141,Extraordinary Inc (Exp),12  Mar-18*,-314.0,HCLI
142,Tax,12  Mar-18*,51.0,HCLI
143,Profit after tax,12  Mar-18*,-2086.0,HCLI
144,Gross profit margin,12  Mar-18*,-3.8,HCLI
145,Effective tax rate,12  Mar-18*,-3.0,HCLI
146,Net profit margin,12  Mar-18*,-5.9,HCLI
147,Current assets,12  Mar-18*,21413.0,HCLI
148,Current liabilities,12  Mar-18*,23718.0,HCLI
149,Net working cap to sales,12  Mar-18*,-6.5,HCLI
150,Current ratio,12  Mar-18*,0.9,HCLI
151,Inventory Days,12  Mar-18*,31.0,HCLI
152,Debtors Days,12  Mar-18*,132.0,HCLI
153,Net fixed assets,12  Mar-18*,1676.0,HCLI
154,Share capital,12  Mar-18*,658.0,HCLI
155,"""Free"" reserves",12  Mar-18*,1695.0,HCLI
156,Net worth,12  Mar-18*,2353.0,HCLI
157,Long term debt,12  Mar-18*,1692.0,HCLI
158,Total assets,12  Mar-18*,28797.0,HCLI
159,Interest coverage,12  Mar-18*,-0.2,HCLI
160,Debt to equity ratio,12  Mar-18*,0.7,HCLI
161,Sales to assets ratio,12  Mar-18*,1.2,HCLI
162,Return on assets,12  Mar-18*,-2.3,HCLI
163,Return on equity,12  Mar-18*,-88.6,HCLI
164,Return on capital,12  Mar-18*,-15.4,HCLI
165,Exports to sales,12  Mar-18*,0.0,HCLI
166,Imports to sales,12  Mar-18*,0.0,HCLI
167,Exports (fob),12  Mar-18*,0.0,HCLI
168,Imports (cif),12  Mar-18*,0.0,HCLI
169,Fx inflow,12  Mar-18*,66.0,HCLI
170,Fx outflow,12  Mar-18*,1219.0,HCLI
171,Net fx,12  Mar-18*,-1153.0,HCLI
172,From Operations,12  Mar-18*,-3508.0,HCLI
173,From Investments,12  Mar-18*,921.0,HCLI
174,From Financial Activity,12  Mar-18*,2347.0,HCLI
175,Net Cashflow,12  Mar-18*,-223.0,HCLI
176,Net Sales,12  Mar-19*,43400.0,HCLI
177,Other income,12  Mar-19*,1024.0,HCLI
178,Total revenues,12  Mar-19*,44424.0,HCLI
179,Gross profit,12  Mar-19*,-971.0,HCLI
180,Depreciation,12  Mar-19*,216.0,HCLI
181,Interest,12  Mar-19*,1230.0,HCLI
182,Profit before tax,12  Mar-19*,-1395.0,HCLI
183,Minority Interest,12  Mar-19*,0.0,HCLI
184,Prior Period Items,12  Mar-19*,0.0,HCLI
185,Extraordinary Inc (Exp),12  Mar-19*,0.0,HCLI
186,Tax,12  Mar-19*,82.0,HCLI
187,Profit after tax,12  Mar-19*,-1477.0,HCLI
188,Gross profit margin,12  Mar-19*,-2.2,HCLI
189,Effective tax rate,12  Mar-19*,-5.9,HCLI
190,Net profit margin,12  Mar-19*,-3.4,HCLI
191,Current assets,12  Mar-19*,14327.0,HCLI
192,Current liabilities,12  Mar-19*,17808.0,HCLI
193,Net working cap to sales,12  Mar-19*,-8.0,HCLI
194,Current ratio,12  Mar-19*,0.8,HCLI
195,Inventory Days,12  Mar-19*,8.0,HCLI
196,Debtors Days,12  Mar-19*,48.0,HCLI
197,Net fixed assets,12  Mar-19*,1420.0,HCLI
198,Share capital,12  Mar-19*,658.0,HCLI
199,"""Free"" reserves",12  Mar-19*,383.0,HCLI
200,Net worth,12  Mar-19*,1042.0,HCLI
201,Long term debt,12  Mar-19*,991.0,HCLI
202,Total assets,12  Mar-19*,19974.0,HCLI
203,Interest coverage,12  Mar-19*,-0.1,HCLI
204,Debt to equity ratio,12  Mar-19*,1.0,HCLI
205,Sales to assets ratio,12  Mar-19*,2.2,HCLI
206,Return on assets,12  Mar-19*,-1.2,HCLI
207,Return on equity,12  Mar-19*,-141.8,HCLI
208,Return on capital,12  Mar-19*,-8.1,HCLI
209,Exports to sales,12  Mar-19*,0.0,HCLI
210,Imports to sales,12  Mar-19*,0.0,HCLI
211,Exports (fob),12  Mar-19*,0.0,HCLI
212,Imports (cif),12  Mar-19*,0.0,HCLI
213,Fx inflow,12  Mar-19*,3.0,HCLI
214,Fx outflow,12  Mar-19*,2073.0,HCLI
215,Net fx,12  Mar-19*,-2069.0,HCLI
216,From Operations,12  Mar-19*,3871.0,HCLI
217,From Investments,12  Mar-19*,1286.0,HCLI
218,From Financial Activity,12  Mar-19*,-4771.0,HCLI
219,Net Cashflow,12  Mar-19*,384.0,HCLI
